SG Americas Securities, LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
SG Americas Securities, LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$3,096
+95.9%
59,439
+138.2%
0.04%
+191.7%
Q2 2023$1,580
-63.0%
24,954
-68.4%
0.01%
-76.0%
Q1 2023$4,272
+231.2%
78,890
+223.7%
0.05%
+212.5%
Q4 2022$1,290
-99.9%
24,369
+9.5%
0.02%
+23.1%
Q3 2022$1,035,000
+27.1%
22,249
+56.0%
0.01%
+44.4%
Q2 2022$814,000
+337.6%
14,262
+370.2%
0.01%
+800.0%
Q1 2022$186,000
-94.1%
3,033
-95.0%
0.00%
-94.1%
Q4 2021$3,153,000
+293.6%
60,248
+180.4%
0.02%
+325.0%
Q3 2021$801,000
-3.8%
21,483
+5.2%
0.00%0.0%
Q2 2021$833,000
+64.3%
20,418
+36.8%
0.00%
+33.3%
Q1 2021$507,000
-87.6%
14,930
-88.4%
0.00%
-86.4%
Q4 2020$4,095,000
+94.2%
128,780
+56.7%
0.02%
+69.2%
Q3 2020$2,109,000
+163.6%
82,190
+163.9%
0.01%
+85.7%
Q2 2020$800,000
+145.4%
31,150
+47.0%
0.01%
+133.3%
Q1 2020$326,000
-11.9%
21,194
+96.8%
0.00%0.0%
Q4 2019$370,000
+270.0%
10,771
+30.8%
0.00%
+200.0%
Q1 2019$100,000
-58.2%
8,235
-60.8%
0.00%
-50.0%
Q4 2018$239,000
-75.2%
21,024
-52.7%
0.00%
-71.4%
Q3 2018$965,000
+407.9%
44,454
+268.6%
0.01%
+250.0%
Q3 2017$190,000
+84.5%
12,060
+45.9%
0.00%
+100.0%
Q2 2017$103,000
-63.3%
8,266
-55.6%
0.00%
-50.0%
Q4 2016$281,000
+142.2%
18,608
+344.3%
0.00%
+100.0%
Q1 2016$116,000
-2.5%
4,188
+40.7%
0.00%0.0%
Q3 2015$119,000
-60.3%
2,977
-83.3%
0.00%
-50.0%
Q2 2014$300,00017,8160.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2023
NameSharesValueWeighting ↓
DCF Advisers, LLC 359,000$18,790,0007.62%
Velan Capital Investment Management LP 150,000$7,851,0006.09%
SILVERARC CAPITAL MANAGEMENT, LLC 195,000$10,206,0004.14%
Vantage Consulting Group Inc 226,670$11,864,0003.19%
Vahanian & Associates Financial Planning Inc. 71,742$3,755,0003.03%
Nicholas Investment Partners, LP 652,886$34,172,0002.16%
COOPER/HAIMS ADVISORS, LLC 61,116$3,199,0001.97%
Bellevue Group AG 3,628,919$189,938,0001.96%
WASATCH ADVISORS LP 8,235,171$431,029,0001.76%
Quantum Private Wealth, LLC 77,622$4,062,0001.54%
View complete list of INTRA CELLULAR THERAPIES INC shareholders